KMA and Co.
  • Why
  • Who
  • What
  • Where
  • Case Studies
  • Reports
  • Blog
Select Page
Digital Therapeutic Investment Soars — is there a bubble in our future?

Digital Therapeutic Investment Soars — is there a bubble in our future?

by Cassie Arnold | Jul 14, 2021 | Biotech Finance, Deal making, Digital Health, Digital Therapeutics, Investment, Venture capital

Digital therapeutic deal-making and venture investment continued up and to the right in the first half of 2021 – far up and to the right.  On the venture side, Rock Health reported that all digital health companies (including those that don’t have patient-facing...
In a Time of COVID, Dealmakers Take a Shine to Diagnostics and Vaccines

In a Time of COVID, Dealmakers Take a Shine to Diagnostics and Vaccines

by Cassie Arnold | Feb 9, 2021 | Biotech Finance, COVID, Deal making, Investment

If you had an inkling that more money went to vaccine and diagnostic companies in 2020, you were right.  Diagnostics and vaccines have long been the red-headed stepchildren of life sciences investments. Detecting and treating life threatening diseases is the...
Digital Therapeutic Deals Make Steady Progress in 2020

Digital Therapeutic Deals Make Steady Progress in 2020

by Cassie Arnold | Jan 28, 2021 | Biotech Finance, Deal making, Digital Health, Digital Therapeutics, Investment

After starting off 2020 with a 35 percent drop in the number of deals from the previous quarter, digital therapeutic deal-making steadily climbed over the course of 2020 to total 71 deals for the year. With 25 deals in the fourth quarter of 2020, the index was up 44...
Counting Deals Instead of Votes

Counting Deals Instead of Votes

by Cassie Arnold | Nov 10, 2020 | Biotech Finance, Deal making, Digital Health, Digital Therapeutic

Tired from a long week of parsing electoral college votes? How about focusing on digital therapeutic deals for a change of pace? The third quarter brought a record number of digital therapeutic deals with a total of 19. That’s up from 16 in the previous quarter. The...
Tracking Digital Therapeutics

Tracking Digital Therapeutics

by Cassie Arnold | Feb 25, 2020 | Biotech Finance, Digital Health, Digital Therapeutic

When I started following the digital health sector in earnest about ten years ago, I was intrigued with the potential of digital technology to treat disease – the so-called digital therapeutics. Instead, the sector produced an almost infinite variety of activity...
Is an Ad Campaign the Solution or the Problem?

Is an Ad Campaign the Solution or the Problem?

by Cassie Arnold | Mar 10, 2017 | Biotech Finance

Is an Ad Campaign the Solution or the Problem? Recently the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade group representing the US pharmaceutical industry, launched an unprecedented image campaign titled “Go Boldly.” The campaign was rolled...
« Older Entries

Newsletter

Subscribe for notifications of new posts, and occasional other news from KMA & Company.




Recent Posts

  • Opportunity Costs
  • Let Me Repeat That
  • Numbers Tell Stories
  • Five Bits of Advice on MarCom Tactics
  • TL;DR*, Less is More, Short and Sweet

Categories

  • 21st Century Culture
  • Advertising
  • Biotech Finance
  • Branding
  • Communications
  • COVID
  • Deal making
  • Digital Health
  • Digital Therapeutic
  • Digital Therapeutics
  • Gender at Work
  • Investment
  • Modern Work
  • Persuasion
  • Sales
  • Venture capital
  • X
  • RSS
Copyright © 2025 KMA & Company